Navigation Links
Par Pharmaceutical Companies Reports Third Quarter 2011 Results
Date:11/2/2011

e second quarter of 2011.  The decrease reflects lower costs as a result of the second quarter branded division restructuring, as well as lower legal and share-based compensation expenses.

Cash and cash equivalents and marketable securitiesThe aggregate balance as of September 30, 2011 was approximately $256.8 million, after $157.6 million in payments during the quarter for previously announced AWP litigation settlements.

Product and Pipeline UpdateIn August, Par Pharmaceutical Companies entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products, for $410 million in cash.  The transaction is expected to close by year-end.

In October, Par Pharmaceutical acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon.  Par now owns the ANDAs of fentanyl citrate lozenges, a generic version of Actiq®, and cyclobenzaprine ER capsules, the generic version of Amrix®, as well as the U.S. rights to market modafinil tablets, the generic version of Provigil®.  Par is currently shipping to the trade all strengths of fentanyl citrate lozenges that were previously available from Teva.

In October, Par Pharmaceutical began shipping all strengths of olanzapine orally disintegrating tablets, the generic version of Lilly's Zyprexa Zydis®.  According to IMS Health data, annual sales in the U.S. of Zyprexa Zydis are approximately $360 million.

Par Pharmaceutical, along with third-party partners, currently has approximately 32 ANDAs pending with the FDA, 13 of which it believes to be first-to-file opportunities.

Conference CallThe Company will host a conference call and live webcast today, Wednesday, November 2, 2011 at 9:00 AM EDT to review results for the third quarter 2011.  
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
(Date:2/26/2015)... Feb. 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... 5,250,000 shares of its common stock at a price ... proceeds to Tandem from this offering are expected to ... and other estimated offering expenses payable by Tandem. All ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  IRIDEX Corporation ... release its fourth quarter and full year 2014 financial results ...   In conjunction with the release, the Company will host ... p.m. Eastern Time on Thursday, March 5, 2015 ... business developments. Interested parties may access the live ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... NORTHRIDGE, Calif., Jan. 4, 2012 Daily doses of ... significantly improved menopausal symptoms, including significantly reducing hot flash ... in postmenopausal Japanese women published in the peer-reviewed ... is believed that S -equol, produced from the ...
... MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. ... Needham & Company, LLC  14th Annual Growth Conference. The ... Wednesday, January 11, 2012 at The New York Palace ... the presentation. In addition, Mr. Krakauer and Seth R. ...
Cached Medicine Technology:New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 2New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 3New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 4New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 5New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 6New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 7
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... 2015 Indosoft Inc , developers ... Asterisk, are pleased to announce the development of Q-Suite ... 5.8 versions of Q-Suite, this new version will include ... of new features to the leading edge call center ... 5.9 will add features to enhance security and protection. ...
(Date:2/28/2015)... 28, 2015 The Mesothelioma Applied ... awards at the International Symposium on Malignant Mesothelioma on ... at the Hyatt Regency Bethesda in Bethesda, Maryland. The ... work and commitment to the mission to cure mesothelioma. ... will be presented to Miriam Ratner. Miriam runs the ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at ... and current student obtaining her Masters degree in social ... forum in psychoeducation on substance use for teens at ... part of her studies. , “Even though these students ... counseling at the high school and junior high school ...
Breaking Medicine News(10 mins):Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... the University of California, San Francisco (UCSF) Medical Center has ... as healthy brain cells begin to form tumors. The ... common type of brain tumor, at its earliest stage, when ... have to prove safe and effective in clinical trials, a ...
... of an oral tablet or vaginal gel containing antiretroviral ... modified because an interim review found that the study ... tenofovir, marketed under the trade name Viread, is effective., ... that the Vaginal and Oral Interventions to Control the ...
... HealthDay Reporter , TUESDAY, Sept. 27 (HealthDay News) ... doesn,t slow decline in thinking skills, a new study ... study participants, risk of death, the researchers found. ... twice as likely to suffer mental impairment as those ...
... LAFAYETTE, Ind. - Purdue University scientists believe they have found ... Xiaoqi Liu, an assistant professor of biochemistry and member ... Liu are focusing on the function of a gene called ... Plk1 is also an oncogene, which tends to mutate and ...
... diagnostic test for Alzheimer,s disease (AD), scientists have discovered that ... of a protein linked to pregnancy years before showing symptoms. ... Theo Luider and colleagues explain that more than ... are rising with the graying of the population. Doctors can ...
... Breast cancer cells that mutate to resist drug treatment ... the drugs as they penetrate the cell membrane making ... Researchers have found a new way to break that ... breast cancer cells to forcibly activate a heat-shock protein called ...
Cached Medicine News:Health News:How normal cells become brain cancers 2Health News:NIH modifies 'VOICE' HIV prevention study in women 2Health News:Super-Tight Blood Sugar Control May Not Ease Mental Decline in Diabetics 2Health News:Super-Tight Blood Sugar Control May Not Ease Mental Decline in Diabetics 3Health News:Gene may be good target for tough-to-kill prostate cancer cells 2Health News:Scientists shut down pump action to break breast cancer cells' drug resistance 2Health News:Scientists shut down pump action to break breast cancer cells' drug resistance 3
Designed as an excellent form of primary suspension...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
... controlled compression and cold, the Calf Cryo/Cuff ... designed cuff provides complete calf coverage for ... a single cuff, or with a cooler ... The Cooler is available separately and can ...
... lightweight orthosis is designed to comfortably ... while allowing unobstructed motion of the ... custom fit the splint may be ... using a heat gun. One cotton ...
Medicine Products: